Toth Financial Advisory Corp Cuts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Toth Financial Advisory Corp decreased its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 57.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,310 shares of the biotechnology company's stock after selling 1,760 shares during the quarter. Toth Financial Advisory Corp's holdings in United Therapeutics were worth $404,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the 4th quarter worth approximately $25,000. Dunhill Financial LLC lifted its holdings in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares during the period. State of Wyoming purchased a new stake in shares of United Therapeutics in the 4th quarter worth $62,000. Curat Global LLC bought a new position in shares of United Therapeutics in the 1st quarter worth $63,000. Finally, Millstone Evans Group LLC bought a new position in shares of United Therapeutics in the 4th quarter worth $67,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Trading Down 1.0%

UTHR traded down $2.79 on Friday, hitting $283.35. 564,424 shares of the company were exchanged, compared to its average volume of 452,608. The firm has a 50-day moving average price of $300.50 and a two-hundred day moving average price of $330.86. The company has a market cap of $12.78 billion, a price-to-earnings ratio of 12.44, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $266.98 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.17 EPS. Equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. JPMorgan Chase & Co. decreased their target price on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Morgan Stanley raised their target price on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Bank of America cut their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $393.08.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer now owns 8,118 shares in the company, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total value of $3,121,580.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $10,437,712.18. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,500 shares of company stock valued at $20,828,390 in the last ninety days. Insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.